A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer. [electronic resource]
Producer: 20100316Description: 69-74 p. digitalISSN:- 1556-1380
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Combined Modality Therapy
- Docetaxel
- Female
- Follow-Up Studies
- Gefitinib
- Humans
- Imaging, Three-Dimensional
- Lung Neoplasms -- drug therapy
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Staging
- Prognosis
- Quinazolines -- administration & dosage
- Radiotherapy Dosage
- Radiotherapy, Conformal
- Survival Rate
- Taxoids -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.